UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Arts and Health: Österreich im internationalen Kontext

1, 2023

Volltextzugriff (PDF)

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance

Molecular cancer therapeutics, 2009-08, Vol.8 (8), p.2086-2095

Perez, Edith A

2009

Volltextzugriff (PDF)

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199

Journal of clinical oncology, 2014-09, Vol.32 (27), p.2959-2966

2014

Volltextzugriff (PDF)

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831

Journal of clinical oncology, 2014-11, Vol.32 (33), p.3744-3752

2014

Volltextzugriff (PDF)

Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order

Drug resistance updates, 2016-01, Vol.24, p.13-22

Perez, Edith A

2016

Volltextzugriff (PDF)

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Journal of clinical oncology, 2013-11, Vol.31 (31), p.3997-4013

2013

Volltextzugriff (PDF)

Treatment of HER2-positive breast cancer: current status and future perspectives

Nature reviews. Clinical oncology, 2012-01, Vol.9 (1), p.16-32

2012

Volltextzugriff (PDF)

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane

Journal of clinical oncology, 2015-02, Vol.33 (6), p.594-601

2015

Volltextzugriff (PDF)

Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study

Journal of clinical oncology, 2015-11, Vol.33 (33), p.3938-3944

2015

Volltextzugriff (PDF)

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

The New England journal of medicine, 2007-12, Vol.357 (26), p.2666-2676

2007

Volltextzugriff (PDF)

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Journal of clinical oncology, 2013-03, Vol.31 (9), p.1157-1163

2013

Volltextzugriff (PDF)

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

Journal of clinical oncology, 2017-01, Vol.35 (2), p.141-148

2017

Volltextzugriff (PDF)

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer

Journal of clinical oncology, 2015-07, Vol.33 (21), p.2353-2360

2015

Volltextzugriff (PDF)

Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial

Journal of clinical oncology, 2016-02, Vol.34 (6), p.581-587

2016

Volltextzugriff (PDF)

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

The lancet oncology, 2014-09, Vol.15 (10), p.1137-1146

2014

Volltextzugriff (PDF)

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1252-1260

2011

Volltextzugriff (PDF)

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

Journal of clinical oncology, 2011-09, Vol.29 (25), p.3366-3373

2011

Volltextzugriff (PDF)

Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120 catenin activity

Nature cell biology, 2015-09, Vol.17 (9), p.1145-1157

2015

Volltextzugriff (PDF)

Folate receptor-α (FOLR1) expression and function in triple negative tumors

PloS one, 2015-03, Vol.10 (3), p.e0122209-e0122209

2015

Volltextzugriff (PDF)

Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries

PloS one, 2015-05, Vol.10 (5), p.e0128345-e0128345

2015

Volltextzugriff (PDF)

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

Archives of pathology & laboratory medicine (1976), 2014-02, Vol.138 (2), p.241-256

2014

Volltextzugriff (PDF)

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

The New England journal of medicine, 2021-12, Vol.385 (25), p.2336-2347

2021

Volltextzugriff (PDF)

Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer

Breast cancer research and treatment, 2009-03, Vol.114 (2), p.195-201

Perez, Edith A

2009

Volltextzugriff (PDF)

Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

The New England journal of medicine, 2008-04, Vol.358 (16), p.1663-1671

2008

Volltextzugriff (PDF)

1 – 25 von 1.837

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.512)
Mit Volltextzugriff
(1.547)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(858)
Life Sciences & Biomedicine
(785)
Humans
(553)
Female
(431)
Oncology
(310)
Biological And Medical Sciences
(240)
Middle Aged
(232)
Breast Neoplasms - Drug Therapy
(228)
Adult
(218)
Medical Sciences
(198)
Aged
(192)
Breast Cancer
(173)
Male
(165)
Tumors
(152)
Breast Neoplasms - Pathology
(131)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(124)
Treatment Outcome
(108)
Food Science & Technology
(93)
Animals
(92)
Aged, 80 And Over
(89)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(1.020)
Ingenta
(661)
MEDLINE
(636)
Journals@Ovid
(471)
IngentaConnect Journals
(384)
Publisher website
(366)
Access via ScienceDirect (Elsevier)
(254)
Springer journals
(162)
Access via Wiley Online Library
(148)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(148)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(120)
Wiley Online Library
(100)
Taylor & Francis
(33)
Access via Taylor & Francis
(32)
Taylor & Francis Online
(31)
Nexis Uni
(31)
Ebook Central Perpetual and DDA
(30)
Access via Oxford University Press
(29)
JSTOR All Journals
(29)
Nature
(28)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(150)
Cancer Research
(46)
Breast Cancer Research And Treatment
(38)
Seminars In Oncology
(29)
Starch - Stärke
(23)
Starch ‐ Stärke
(23)
Cancer
(21)
Plos One
(21)
Starch-Starke
(21)
Mayo Clinic Proceedings
(19)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Arts and Health: Österreich im internationalen Kontext

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831

Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Treatment of HER2-positive breast cancer: current status and future perspectives

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane

Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer

Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120 catenin activity

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

Folate receptor-α (FOLR1) expression and function in triple negative tumors

Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer

Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

Suchergebnisse filtern